Amanta Healthcare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹9(7.14%)
Premium (ELP)
Following its successful public offering, Amanta Healthcare Limited's made its market debut on Sep 09, 2025 and is now actively traded on the NSE, BSEplatform. The IPO mobilized 1,00,00,000 Shares in total capital, including 1,00,00,000 Shares in primary equity infusion.
The offering was structured with a price band of ₹120 to ₹126 and minimum investment lots of 119 shares. Investor participation during the subscription window from Sep 01, 2025 to Sep 03, 2025 demonstrated market confidence in the company's prospects.
The allotment process concluded on Sep 04, 2025, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Amanta Healthcare Limited, founded in December 1994, is a pharmaceutical company engaged in developing, manufacturing, and marketing sterile liquid products, mainly parenteral formulations, using advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies. The company also produces medical devices and offers a wide range of products including IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, first-aid items, and eye lubricants. Its business is divided into three units: national sales, international sales, and product partnerships with Indian and global pharmaceutical companies. Amanta manufactures over 45 generic products, distributed across India through 320 distributors and stockists, while also exporting to Africa, Latin America, the UK, and other regions. Its products are registered in 19 countries, and in Fiscal 2025, it exported branded products to 21 countries. As of March 31, 2025, the company employed 1,718 people across its formulation, development, and quality laboratories.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Increasing Healthcare Access: greater reach of medicines and insurance fueling pharma demand
- Policy Support: government schemes, tax incentives, and subsidies driving sector growth
- Strong Talent Base: vast pool of scientists and researchers enhancing pharma capabilities
- Single Facility Dependence: reliance on one Gujarat unit makes operations vulnerable to power issues, accidents, or disasters
- Production & Quality Concerns: delays or defects may cause cancellations and client loss
- Litigation Challenges: ongoing cases could harm business, finances, and growth plans
- Bhavesh Patel
- Vishal Patel
- Jayshreeben Patel
- Jitendra Kumar Patel
- Milcent Appliances Private Limited
Amanta Healthcare Limited
Link Intime India Private Limited